CD4 and B-cell chronic lymphocytic leukemia: have demonstrated the enduring impact of CAR-T cell therapy in treating chronic lymphocytic leukemia (CLL), particularly in tracking the persistence and development of CD4+ CAR-T cells over a decade (40).